Natera controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile6 entries
2021
Natera sues Inivata over alleged patent infringement
Lawsuit filed
In a lawsuit, Natera filed claims against Inivata Ltd. and its wholly owned subsidiary, alleging infringement of two U.S. patents. Natera seeks injunctive relief and monetary damages. The allegations are claims asserted in the lawsuit and are not a stated court determination. The filing concerns the alleged patent infringement and the relief sought by Natera.
Natera filed a lawsuit against Inivata Ltd. and its wholly owned subsidiary, alleging infringement of two U.S. patents. Natera seeks injunctive relief and monetary damages; the allegations are claims in the lawsuit, not a stated court determination.
Source excerpt
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned subsidiary Inivata, Inc. for alleged infringement of Natera's U.S. Patent Nos. 10,262,755 and 10,597,709.
Natera is seeking both injunctive relief and monetary damages.
2021
Guardant Health sues Natera over alleged advertising claims
Lawsuit filed
Guardant Health sued Natera, alleging that Natera ran a campaign of false and misleading advertising concerning Guardant's Reveal cancer assay and made unfounded comparisons with its own product. These are allegations in the lawsuit.
Source excerpt
Guardant Health Inc., an oncology company based in Delaware, sued Natera, Inc. on Thursday over allegations that Natera has led a “campaign of false and misleading advertising,” in regard to Guardant’s product, called the Guardant Reveal liquid biopsy cancer assay (Reveal) for early-stage colorectal cancer (CRC).
The defendants are said to have misrepresented Reveal, as they describe their product Signatera as one that is superior in sensitivity, failure rate, negative predictive value, and Hazard Ratio.
2020
Natera files patent infringement suit against CareDx
Lawsuit filed
Natera announced that it filed a lawsuit against CareDx alleging infringement of Natera's U.S. Patent 10,526,658. The announcement presents Natera's allegation; it does not state that a court has reached a determination in the matter. The source describes the filing as a patent infringement suit brought by Natera against CareDx.
Natera said it filed suit against CareDx alleging infringement of Natera's U.S. Patent 10,526,658. The article reports the allegation, not a court determination.
Source excerpt
today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent").
2020
Natera files patent suit against Progenity
Lawsuit filed
Natera filed suit against Progenity in the U.S. District Court for the Western District of Texas, alleging that Progenity's use and sale of its non-invasive prenatal test infringed six patents. Natera sought injunctive relief and monetary damages. The source reports allegations, not a court determination.
Source excerpt
filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242 (the "Asserted Patents").
The suit was filed in the U.S. District Court for the Western District of Texas, and alleges that the use and sale of Progenity's non-invasive prenatal test infringe the six Asserted Patents.
2020
Natera sues ArcherDX over patent infringement
Lawsuit filed
Natera filed suit against ArcherDX in the U.S. District Court of Delaware. Natera's complaint alleges that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes Natera's patent; the allegation is not presented as a court determination.
Source excerpt
Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent").
2018
Federal billing and sales settlement
Natera paid an $11 million settlement to the United States Department of Justice over allegations involving improper billing and sales of Panorama testing to federal health-care programs during 2013–2016.